Review Article
New Insights in the Diagnosis and Treatment of Heart Failure
Table 1
Recent studies in heart failure with reduced ejection fraction.
| Study | Type | Drug/comp. |
Number of pts/Age | Outcome | Results |
| ARS | PoC | Finerenone (BAY 94-8862) (nonsteroidal MRA) | 458/72 | Safety and tolerability in chronic kidney disease versus spironolactone | Significantly lower incidences of hyperkalemia than spironolactone |
| ATMOSPHERE | Outcome | Aliskiren (direct renin inhibitors) | 7000 | Cardiovascular death or HF hospitalization versus enalapril | Ongoing |
| LEPTH | Outcome | Riociguat (guanylate cyclase stimulator) | 201/59 | Change in mean pulmonary artery pressure | Not met but improved stroke volume and cardiac index and reduced pulmonary and systemic vascular resistance |
| SOCRATES-REDUCED | PoC | Vericiguat (guanylate cyclase stimulator) | 410 | Change in NT-proBNP | Ongoing |
| PARADIGM-HF | Outcome | LCZ696 (ARNI, angiotensin II receptor blocker and neprilysin inhibitor) | 8442/63 | Death from cardiovascular causes or a first hospitalization for heart failure | LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure |
| RED-HF | Outcome | Darbepoetin Alfa | 2278/72 | Death or hospitalization in patients with Hb (9.0–12.0 g/dL) | Not met but improved haemoglobin level |
| FAIR-HF | PoC | Intravenous iron (ferric carboxymaltose) | 459/67 | Self-reported Patient Global Assessment and NYHA functional class | Improvements in 6-minute walk test and quality of life assessment |
| ICHF | PoC | Intravenous iron (ferric carboxymaltose) | | Improvement in LVEF | Ongoing |
| MOOD-HF | Outcome | Escitalopram (serotonin reuptake inhibitor) | 700 | Death or hospitalization | Ongoing |
|
|
PoC, proof-of-concept.
|